Projects

Research Partnerships

ctMoniTR Project

ctDNA is genetic material from cancer cells naturally found in the bloodstream. ctDNA to Monitor Treatment Response (ctMoniTR) is a first of its kind partnership to answer the question: Do changes in ctDNA reflect response to treatment?

HRD Harmonization Project

The Homologous Recombination Deficiency (HRD) Harmonization Project will support future use of assays that measure HRD for treatment decision making by examining sources of variability across tests and identifying opportunities for alignment.

TMB Harmonization Project

The Tumor Mutational Burden (TMB) Harmonization Project supports the use of assays that measure TMB for treatment decision making by examining sources of variability across assays and identifying opportunities for alignment.

Real-World Evidence Portfolio

The Friends of Cancer Research Real-World Evidence portfolio develops and establishes methodology for using RWD to demonstrate benefit to patients.

Cell & Gene Therapies

Advancements in cancer immunology and recent clinical experience with emerging cellular therapeutics have the potential to rapidly change cancer treatment and represents a new treatment paradigm.

Clinical Trial Eligibility Criteria

The American Society of Clinical Oncology and Friends of Cancer Research jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients.

COVID-19

The COVID-19 Evidence Accelerator is an initiative launched by the Reagan-Udall Foundation for the FDA in collaboration with Friends of Cancer Research to provide a unique venue for major data organizations, government and academic researchers, and health systems to gather and design quick turnaround queries and share their results.

Lung-MAP

Lung-MAP is a first-of-its-kind clinical trial model that uses a multi-drug, targeted screening approach to match patients with sub-studies testing investigational new treatments based on their unique tumor profiles.

Tolerability & Dosing

Friends of Cancer Research has convened a multi-stakeholder working group to develop a working definition of tolerability that better encompasses patient experience.

Data Driven Insights

Friends has created a series of interactive dashboards as a tool to gain data driven insights into the landscape of oncology drug development and FDA drug approvals.

Breakthrough Therapies

Working with our partners in all sectors, Friends took ‘Breakthrough’ from concept, to scientific whitepaper, to bipartisan legislative solution, to a tool in full use by FDA to expedite the approval of multiple drugs in 13 months.

About Breakthrough Therapies

Search Breakthrough Therapies